Varenicline in the Treatment of Alcohol Use Disorders
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objective: To summarize the efficacy and safety data for the use of varenicline in the treatment of alcohol use disorders. Data Sources: A literature search was conducted in PubMed, International Pharmaceutical Abstracts, and Cochrane Library (through May 2014). Key search terms included varenicline, alcohol, alcohol dependence, alcoholism, ethanol, and nicotinic acetylcholine receptor. Additional references were identified from literature citations. Study Selection and Data Extraction: Results were limited to clinical trials and case reports that discussed either the use of varenicline in alcohol drinking patients or adverse effects experienced with its use. Only English language studies in humans were reviewed. Data Synthesis: In all, 7 randomized, placebo-controlled clinical trials and 1 open-label study were identified that evaluated the impact of varenicline on various drinking-related end points. The studies were conducted in patients dependent on alcohol (n = 4), non-alcohol-dependent patients (n = 3), and patients with a history of alcohol dependence but who had been abstinent for at least 6 months (n = 1). The majority of the studies classified their participants as heavy drinkers; however, this definition varied across studies. Most studies included smokers, but 2 trials included both smokers and nonsmokers. Conclusions: Evidence supports the use of varenicline for the reduction of alcohol craving as well as for the reduction of overall alcohol consumption in patients with alcohol use disorders. However, it is not likely to improve abstinence rates. Although most of the data were derived from patients with concurrent nicotine dependence, the effects of varenicline appear to occur independent of baseline smoking status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287 · cited 6×
“The investigators found that outcomes did not differ significantly between baseline smokers and nonsmokers.(6) Results from a second clinical trial (n = 40) evaluating various subjective and objective drinking measures were also published in 2013.”
BackgroundInfluentialVarenicline, Smoking Cessation, and Neuropsychiatric Adverse Events
Gibbons, R. D., & Mann, J. J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12121599 · Cited by 142 · cited 2×
“The results showed that nicotine replacement therapy was actually associated with higher rates of neuropsychiatric disorders than varenicline.(31) Two cases of acute liver injury with varenicline have been reported in the literature.”
Cited by
Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?
Mann, K., Aubin, H.-J., & Witkiewitz, K. (2017) · European Addiction Research · doi:10.1159/000481348 · Cited by 93
Effects of dulaglutide on alcohol consumption during smoking cessation
Probst, L., Monnerat, S., Vogt, D. R., Lengsfeld, S., Burkard, T., Meienberg, A., Bathelt, C., Christ-Crain, M., & Winzeler, B. (2023) · JCI Insight · doi:10.1172/jci.insight.170419 · Cited by 94
“Varenicline has been found to reduce alcohol intake, especially in smokers, but also independently of smoking status (28).”
BackgroundChander, G., Hutton, H. E., Lau, B., Xu, X., & McCaul, M. E. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000679 · Cited by 83
Treatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
“abnormal dreams and dry mouth were more often reported compared to placebo (Erwin and Slaton, 2014; Raich et al., 2016).”
Background
Metadata
- Authors
- Erwin, B. L., & Slaton, R. M.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2014-08-05
- Volume
- 48
- Issue
- 11
- Pages
- 1445-1455
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2102817517
- Cited by
- 63
- References
- 2
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Varenicline in the Treatment of Alcohol Use Disorders. https://app.cochat.ai/papers/10.1177/1060028014545806
- The paper
- Erwin, B. L., & Slaton, R. M. (2014). Varenicline in the Treatment of Alcohol Use Disorders. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028014545806
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.